IL135188A0 - Vitronectin receptor antagonist - Google Patents
Vitronectin receptor antagonistInfo
- Publication number
- IL135188A0 IL135188A0 IL13518898A IL13518898A IL135188A0 IL 135188 A0 IL135188 A0 IL 135188A0 IL 13518898 A IL13518898 A IL 13518898A IL 13518898 A IL13518898 A IL 13518898A IL 135188 A0 IL135188 A0 IL 135188A0
- Authority
- IL
- Israel
- Prior art keywords
- receptor antagonist
- vitronectin receptor
- vitronectin
- antagonist
- receptor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5986797P | 1997-09-24 | 1997-09-24 | |
| PCT/US1998/019987 WO1999015178A1 (en) | 1997-09-24 | 1998-09-24 | Vitronectin receptor antagonist |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL135188A0 true IL135188A0 (en) | 2001-05-20 |
Family
ID=22025805
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL13518898A IL135188A0 (en) | 1997-09-24 | 1998-09-24 | Vitronectin receptor antagonist |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP1023073A1 (en) |
| JP (1) | JP2002500162A (en) |
| KR (1) | KR20010024249A (en) |
| CN (1) | CN1271284A (en) |
| AU (1) | AU9578798A (en) |
| BR (1) | BR9813214A (en) |
| CA (1) | CA2304000A1 (en) |
| HU (1) | HUP0003931A2 (en) |
| IL (1) | IL135188A0 (en) |
| NO (1) | NO20001515L (en) |
| PL (1) | PL339414A1 (en) |
| TR (1) | TR200000786T2 (en) |
| WO (1) | WO1999015178A1 (en) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2358855A1 (en) | 1999-02-03 | 2000-08-10 | Merck & Co., Inc. | Benzazepine derivatives as alpha-v integrin receptor antagonists |
| US6514964B1 (en) | 1999-09-27 | 2003-02-04 | Amgen Inc. | Fused cycloheptane and fused azacycloheptane compounds and their methods of use |
| JP4660067B2 (en) | 2001-04-24 | 2011-03-30 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | Combination therapy using an anti-angiogenic agent and TNFα |
| KR20040058229A (en) | 2001-10-22 | 2004-07-03 | 더 스크립스 리서치 인스티튜트 | Antibody targeting compounds |
| EP1628949A4 (en) * | 2003-04-04 | 2008-07-02 | Smithkline Beecham Corp | Process and intermediates for preparing benzazepines |
| EP1711614B1 (en) | 2004-02-02 | 2009-01-07 | Pioneer Hi-Bred International, Inc. | Ap2 domain transcription factor odp2 (ovule development protein 2) and methods of use |
| UA87854C2 (en) | 2004-06-07 | 2009-08-25 | Мерк Энд Ко., Инк. | N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators |
| ES2521679T3 (en) | 2006-01-18 | 2014-11-13 | Merck Patent Gmbh | Specific therapy using integrin ligands for cancer treatment |
| DK2101805T3 (en) | 2007-01-18 | 2013-01-21 | Merck Patent Gmbh | INTEGRIC LANDS FOR USE IN CANCER TREATMENT |
| AU2008321770B2 (en) | 2007-11-16 | 2012-09-06 | Ube Industries, Ltd. | Benzazepinone compound |
| US8076475B2 (en) * | 2008-03-06 | 2011-12-13 | Glaxosmithkline Llc | Process |
| US8518927B2 (en) | 2009-02-10 | 2013-08-27 | The Scripps Research Institute | Chemically programmed vaccination |
| WO2010113958A1 (en) | 2009-03-30 | 2010-10-07 | 宇部興産株式会社 | Pharmaceutical composition for treatment or prevention of ophthalmic diseases |
| MX2011012491A (en) | 2009-05-25 | 2011-12-14 | Merck Patent Gmbh | Continuous administration of cilengitide in cancer treatments. |
| EP2529018B1 (en) | 2009-12-30 | 2016-06-22 | Pioneer Hi-Bred International, Inc. | Methods and compositions for the introduction and regulated expression of genes in plants |
| AU2010339481B2 (en) | 2009-12-30 | 2016-02-04 | Pioneer Hi-Bred International, Inc. | Methods and compositions for targeted polynucleotide modification |
| JP6649902B2 (en) | 2014-05-30 | 2020-02-19 | ファイザー・インク | Carbonitrile derivatives as selective androgen receptor modulators |
| WO2023275715A1 (en) | 2021-06-30 | 2023-01-05 | Pfizer Inc. | Metabolites of selective androgen receptor modulators |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA60311C2 (en) * | 1996-10-02 | 2003-10-15 | Смітклайн Бічам Корпорейшн | Vitronectin receptor antagonists |
-
1998
- 1998-09-24 JP JP2000512547A patent/JP2002500162A/en not_active Withdrawn
- 1998-09-24 CN CN98809494A patent/CN1271284A/en active Pending
- 1998-09-24 PL PL98339414A patent/PL339414A1/en unknown
- 1998-09-24 HU HU0003931A patent/HUP0003931A2/en unknown
- 1998-09-24 CA CA002304000A patent/CA2304000A1/en not_active Abandoned
- 1998-09-24 EP EP98949471A patent/EP1023073A1/en active Pending
- 1998-09-24 WO PCT/US1998/019987 patent/WO1999015178A1/en not_active Application Discontinuation
- 1998-09-24 KR KR1020007003093A patent/KR20010024249A/en not_active Application Discontinuation
- 1998-09-24 AU AU95787/98A patent/AU9578798A/en not_active Abandoned
- 1998-09-24 BR BR9813214-8A patent/BR9813214A/en not_active Application Discontinuation
- 1998-09-24 TR TR2000/00786T patent/TR200000786T2/en unknown
- 1998-09-24 IL IL13518898A patent/IL135188A0/en unknown
-
2000
- 2000-03-23 NO NO20001515A patent/NO20001515L/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1023073A1 (en) | 2000-08-02 |
| KR20010024249A (en) | 2001-03-26 |
| NO20001515D0 (en) | 2000-03-23 |
| HUP0003931A2 (en) | 2001-10-28 |
| NO20001515L (en) | 2000-03-23 |
| TR200000786T2 (en) | 2000-08-21 |
| BR9813214A (en) | 2000-08-29 |
| AU9578798A (en) | 1999-04-12 |
| CN1271284A (en) | 2000-10-25 |
| WO1999015178A1 (en) | 1999-04-01 |
| PL339414A1 (en) | 2000-12-18 |
| CA2304000A1 (en) | 1999-04-01 |
| JP2002500162A (en) | 2002-01-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1000031A4 (en) | Vitronectin receptor antagonist | |
| CY2576B1 (en) | Vitronectin receptor antagonists | |
| EP0767792A4 (en) | Vitronectin receptor antagonists | |
| ZA955391B (en) | Vitronectin receptor antagonists | |
| IL130760A0 (en) | Vitronectin receptor antagonists | |
| IL142958A0 (en) | Vitronectin receptor antagonist pharmaceuticals | |
| HUP9900754A3 (en) | Vitronectin receptor antagonists | |
| EP0895475A4 (en) | Vitronectin receptor antagonists | |
| IL135189A0 (en) | Vitronectin receptor antagonist | |
| IL135188A0 (en) | Vitronectin receptor antagonist | |
| IL138245A0 (en) | Vitronectin receptor antagonists | |
| IL135028A0 (en) | Vitronectin receptor antagonists | |
| EG24025A (en) | Vitronectin receptor antagonist | |
| PL346157A1 (en) | Vitronectin receptor antagonists | |
| ZA988562B (en) | Vitronectin receptor antagonists | |
| GB9811295D0 (en) | Vitronectin receptor antagonists | |
| GB9822331D0 (en) | Vitronectin receptor antagonists | |
| GB9815803D0 (en) | Vitronectin receptor antagonists | |
| GB9807382D0 (en) | Vitronectin receptor antagonists | |
| GB9807384D0 (en) | Vitronectin receptor antagonists | |
| GB9810892D0 (en) | Vitronectin receptor antagonists | |
| GB9810882D0 (en) | Vitronectin receptor antagonists | |
| GB9810182D0 (en) | Vitronectin receptor antagonists | |
| GB9812686D0 (en) | Vitronectin receptor antagonists | |
| SI0957917T1 (en) | Vitronectin receptor antagonists |